ALXN News and Press, Alexion Pharmaceuticals Inc. From 12/09/19

Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020. This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA. This is in no way a thorou...

Today, we will be studying why Dicerna Pharmaceuticals ( DRNA ) is an attractive investment for 2020. Company overview Dicerna Pharmaceuticals is a small-cap biopharmaceutical company focused on developing innovative RNAi (RNA interference) therapies. The company is predominantly targeti...

In a statement , Alexion Pharmaceuticals (NASDAQ: ALXN ) says it has established a "strong foundation" to drive growth and boost shareholder value and does not plan to pursue an outright sale as proposed by shareholder Elliott Advisors. More news on: Alexion Pharmaceuticals, Inc., Healthc...

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today issued the following statement on behalf of the Board of Directors and management team: "The Board and management team are focused on delivering long-term shareholder value by advancing our mission of developing and delivering transforma...

iShares Nasdaq Biotechnology ETF ( IBB ) has been moving in the right direction lately, mostly because the risk of an aggressive healthcare reform that could dramatically affect pricing power for biotech stocks has significantly declined in recent months. Moving forward, the ETF still has a ...

Topline data from an initial six-subject cohort in an open-label, single-arm  Phase 2 clinical trial evaluating Regeneron Pharmaceuticals' (NASDAQ: REGN ) pozelimab (REGN3918) in patients with paroxysmal nocturnal hemoglobinuria (PNH) showed a positive effect. More news on: Regene...

ChemoCentryx ( CCXI ) and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that they had achieved positive results from the phase 3 study treating patients with ANCA-associated vasculitis using the drug Avacopan. What makes these results substantial is that pati...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 2019 Evercore ISI HealthCONx in Boston, MA on Tuesday, December 3rd, 2019 at 8:45 a.m. ET. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexi...

The biotech sector continues to grow as valuations are sky high, based on recent M&A’s within the industry. 2019 started off with a boom with the announcement of two multi-billion-dollar deals valued at a total $82 billion, one of them being among the top 10 highest valuations of a...

Alexion Pharmaceuticals (NASDAQ: ALXN ) says Japan's Ministry of Health, Labour and Welfare has approved the extension of the current marketing authorization of Soliris (eculizumab) for the prevention of relapse in patients with NMOSD. More news on: Alexion Pharmaceuticals, Inc., Heal...